ClinicalTrials.gg
CompletedNCT04425291Updated Feb 25, 2022

Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

A Phase 3 interventional study of 4-valent HPV Vaccine and 9-valent HPV Vaccine in Cervical Cancer, Vulvar Cancer and Vaginal Cancer, sponsored by Shanghai Bovax Biotechnology Co., Ltd.. Completed at 1 site in China. Open to female participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-02-25.

Sponsored by Shanghai Bovax Biotechnology Co., Ltd. · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,680
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 14 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Uterine Cervical Neoplasms — 6 open to participants now, 8 under way, 3 of them phase 3. Human Papillomavirus Recombinant Vaccine nonavalent · Uterine Cervical Neoplasms.

Enrollment
5th of 14
1,680 · median 1,206
Started
2020
with 1 other
Phase 3
9 of 14
2 open now
Registered
8th of 14
by date
Lead sponsor
2 of 14
Shanghai Bovax Biotechnology Co., Ltd.

Among the 14 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Uterine Cervical Neoplasms, this one is the 5th largest by enrollment, is one of 2 that started in 2020, is one of 9 in phase 3, and was the 8th registered.

Uterine Cervical Neoplasms

2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

6 of the 14 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Uterine Cervical Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About Human Papillomavirus Recombinant Vaccine nonavalent

Human Papillomavirus Recombinant Vaccine nonavalent: first FDA approval 2014 (Gardasil 9). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 474 Uterine Cervical Neoplasms studies recruiting now, 244 (51%) set no upper age limit and 190 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 20 Years to 45 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Uterine Cervical Neoplasms, or all of them as a file.
02

Study summary

The study will evaluate the immunogenicity and safety of 4-valent and 9-valent HPV recombinant vaccine in Chinese healthy females 20 to 45 years of age.

03

Conditions studied

  • Cervical Cancer
  • Vulvar Cancer
  • Vaginal Cancer
  • CIN1
  • CIN2
  • CIN3
  • VaIN1
  • VaIN2
  • VaIN3
  • Genital Wart
  • VIN 1
  • VIN 2
  • VIN 3
  • AIS
04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Chinese women aged 20-45 who can provide legal identification;
  2. The subject agreed to participate in the study, and voluntarily signs the ;
  3. Subjects are able to understand the study procedures and participate in follow-up according to the study requirements;
  4. When the subjects were enrolled, the urine pregnancy test was negative, they were not in the lactation period and had no family planning within 7 months after enrollment.2 weeks before included in the study, effective measures has been adopted and agreed to in the first seven months after the study (vaccinations after 1 months ago) continue to adopt effective contraceptive measures (effective contraceptive measures including the pill or condoms, etc );

Exclusion criteria

Exclusion Criteria:

  1. Have been vaccinated with commercially available HPV vaccine in the past or planned to be vaccinated with commercially available HPV vaccine during the study period;Or have participated in a clinical trial of the HPV vaccine;
  2. Has a history of cervical diseases, such as cervical screening showing abnormal results including CIN or a history of hysterectomy (vaginal or total abdominal hysterectomy) or pelvic radiation therapy. Has a history of genital diseases (such as vulvar intraepithelial neoplasia, vaginal intraepithelial neoplasia, genital warts, vulvar cancer, vaginal cancer and anal cancer, etc.) or has a previous sexual history (including syphilis, gonorrhea, chancre, venereal lymphatic granuloma, granuloma inguinal);
  3. A history of severe allergies requiring medical intervention, such as anaphylactic shock, anaphylactic laryngeal edema, allergic purpura, thrombocytopenic purpura, local allergic necrosis reaction (Arthus reaction), etc;
  4. Have an acute illness or an acute episode of a chronic illness within 3 days prior to vaccination or the use of antipyretic, analgesic and antiallergic drugs (e.g., acetaminophen, ibuprofen, aspirin, loratadine, cetirizine, etc.);
  5. Subjects received inactivated or recombinant vaccines within 14 days prior to study enrollment, or attenuated within 28 days prior to study enrollment;
  6. Subjects present with immune impairment or have been diagnosed with congenital or acquired immune deficiency, infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), inflammatory bowel disease or other diseases. Long-term therapy, e.g., long-term (more than 2 weeks) treatment with (e.g., prednisone or similar drugs);
  7. Has been diagnosed with a severe congenital malformation or chronic disease such as Down syndrome, heart disease, liver disease, kidney disease, diabetes, etc., which may interfere with the conduct or completion of the study;
  8. Subject receives any immunoglobulin or blood product within 3 months prior to the first dose of vaccination;
  9. Participating in other (drug or vaccine) clinical trials prior to enrollment or planning to participate during the study;
  10. Has been diagnosed with an infectious disease, such as tuberculosis, viral hepatitis and/or HIV infection;
  11. A history or family history of convulsions, epilepsy, encephalopathy and mental illness;
  12. Have to intramuscular injection, such as having been diagnosed with thrombocytopenia, any coagulation disorder or receiving anticoagulant therapy;
  13. Absence of a spleen, functional absence of a spleen, and absence or removal of a spleen in any case;
  14. Body temperature ≥37.3℃ (underarm body temperature);
  15. Subjects may be unable to comply with the study procedure, comply with the agreement, or plan to permanently relocate from the region prior to completion of the study, or may be permanently absent from the region during the scheduled visit;
  16. In the opinion of the investigators, the subjects had any other factors that made them unsuitable to participate in the clinical trial.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,680 participants (actual)

Study arms

  • Experimental
    4-valent HPV Vaccine

    Participants in this arm would receive 4-valent Human Papillomavirus (Types 6, 11, 16 and18) Recombinant Vaccine (Hansenula Polymorpha)

    Biological: 4-valent HPV Vaccine

  • Experimental
    9-valent HPV Vaccine

    Participants in this arm would receive 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha)

    Biological: 9-valent HPV Vaccine

  • Active comparator
    GARDASIL®

    Participants in this arm would receive GARDASIL®

    Biological: GARDASIL®

Interventions

  • Biological4-valent HPV Vaccine

    Subjects received 3 doses of 4-valent HPV vaccine according to a 0, 2, 6-month schedule.

  • Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule.

  • BiologicalGARDASIL®

    Subjects received 3 doses of GARDASIL® according to a 0, 2, 6-month schedule.

06

What researchers measure

Primary outcomes

  1. Percentage of participants 20 to 45 Years of Age that achieve the neutralizing antibody serostatus cutoffs for seroconversion to HPV Types 6, 11, 16 and 18 at least 1 month post Dose 3.

    Time frame: 1 month post vaccination 3 (Month 7)

Secondary outcomes

  1. The neutralizing antibody GMTs for HPV Types 6, 11, 16 and 18 in participants 20 to 45 Years of Age at least 1 month post Dose 3.

    Time frame: 1 month post vaccination 3 (Month 7)

  2. Percentage of participants that achieve neutralizing antibody quadruple growth ratefor HPV Types 6, 11, 16 and 18 in participants 20 to 45 Years of Age at least 1 month post Dose 3.

    Time frame: 1 month post vaccination 3 (Month 7)

  3. Percentage of participants that achieve neutralizing antibody quadruple growth rate or achieve the neutralizing antibody serostatus cutoffs for HPV Types 6, 11, 16 and 18 in participants 20 to 45 Years of Age at least 1 month post Dose 3.

    Time frame: 1 month post vaccination 3 (Month 7)

  4. The neutralizing antibody GMTs for HPV Types 31, 33, 45 and 52 in participants 20 to 45 Years of Age at least 1 month post Dose 3.

    Time frame: 1 month post vaccination 3 (Month 7)

  5. Percentage of participants that achieve neutralizing antibody quadruple growth ratefor HPV Types 31, 33, 45 and 52 in participants 20 to 45 Years of Age at least 1 month post Dose 3.

    Time frame: 1 month post vaccination 3 (Month 7)

  6. Percentage of participants that achieve neutralizing antibody quadruple growth rate or achieve the neutralizing antibody serostatus cutoffs for HPV Types 31, 33, 45 and 52 in participants 20 to 45 Years of Age at least 1 month post Dose 3.

    Time frame: 1 month post vaccination 3 (Month 7)

  7. Percentage of Participants Who Report at Least 1 Solicited Injection-site and Systemic Adverse Event 30 minutes post any vaccination

    Time frame: 30 minutes post any vaccination

  8. Percentage of Participants Who Report at Least 1 Solicited Adverse Event 7 days post any vaccination

    Time frame: 7 days post any vaccination

  9. Percentage of Participants Who Report at Least 1 Solicited and Unsolicited Adverse Event 30 days post any vaccination

    Time frame: 30 days post any vaccination

  10. Percentage of Participants Who Experience at Least 1 Serious Adverse Event (SAE) from 1st vaccination to the completion of study

    Time frame: Day 1 to 6 months post vaccination 3

  11. Percentage of Participants Who Experience Pregnancy from 1st vaccination to the completion of study

    Time frame: Day 1 to 6 months post vaccination 3

07

Study locations

1 site
  • Yangchun Center For Disease Prevention And Control
    Yangchun, Guangdong, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2020 to primary completion in Sep 2021, 15 months.

Of 46 industry-sponsored phase 3 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 55. This study's 15 months is below that.

Counting every sponsor, half of 99 studies reached it within 55 months; a quarter within 24 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2020
First posted
Jun 11, 2020
StartActual
May 28, 2020
Primary completionActual
Sep 6, 2021
CompletionActual
Sep 6, 2021
Last update
Feb 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04425291
Lead sponsor
Shanghai Bovax Biotechnology Co., Ltd.
Collaborators
Chongqing Bovax Biopharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Jun 11, 2020
Start date
May 28, 2020
Primary completion
Sep 6, 2021
Completion
Sep 6, 2021
Last update
Feb 25, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Papillomavirus Recombinant Vaccine nonavalent

Start the discussion